Ulcer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Peptic ulcer disease (PUD) encompasses ulcerating lesions in the gastric and duodenal mucosa resulting from imbalance between aggressive factors (hydrochloric acid, pepsin, H. pylori virulence factors, NSAIDs) and protective mucosal defenses (mucus, bicarbonate, prostaglandins, mucosal blood flow). Ulcers are defined as mucosal breaks exceeding 5 mm in diameter penetrating through the muscularis mucosae, distinguishing them from superficial erosions. Globally, PUD affects approximately 4 million people annually with a lifetime prevalence of 5–10% in Western populations and higher rates in H. pylori–endemic regions.

Helicobacter pylori infection, a gram-negative spiral bacterium colonising the gastric antrum and body, is the primary causative factor in 60–70% of gastric ulcers and 90–95% of duodenal ulcers. H. pylori induces chronic active gastritis, impairs mucosal defence, elevates gastrin and acid output, and promotes ulcerogenesis through virulence factors including CagA protein and VacA cytotoxin. NSAID use — aspirin, ibuprofen, naproxen, diclofenac — is the second major cause, responsible for 20–25% of ulcers through COX-1 inhibition impairing prostaglandin-mediated mucosal cytoprotection, independently of H. pylori status.

Medical therapy has transformed PUD management. Proton pump inhibitors (PPIs) — omeprazole, lansoprazole, esomeprazole, pantoprazole — are the cornerstone of acid suppression, reducing 24-hour intragastric acidity by 90%+ and healing 80–95% of duodenal ulcers in 4 weeks and 85–90% of gastric ulcers in 8 weeks. Combined with H. pylori eradication regimens (14-day triple or bismuth quadruple therapy achieving 85–95% eradication rates), modern medical therapy has reduced the need for elective ulcer surgery by over 90% since the 1980s.

Duodenal ulcers occur in the first part of the duodenum (D1) and are the most common form of PUD, predominantly affecting younger adults aged 30–50. Classic presentation: epigastric pain that wakes patients at night, relieved by food or antacids (acid neutralisation in the duodenum). Helicobacter pylori is present in over 90% of duodenal ulcer patients not using NSAIDs.

Gastric ulcers occur most commonly in the lesser curvature and antrum, affecting older adults (peak age 50–70). Pain often worsens with eating (acid stimulus). NSAID use, H. pylori, and delayed gastric emptying are important contributors. All gastric ulcers require follow-up endoscopy after treatment to confirm healing and exclude malignancy — biopsies are taken from the ulcer edge at index endoscopy.

Complicated PUD includes: upper GI hemorrhage (presentation: hematemesis, melena, or hematochezia; occurs in 15–20% of ulcer patients — the most common serious complication requiring emergency endoscopy); perforation (1–2% of ulcers; presents as sudden severe abdominal pain with peritoneal signs; requires urgent surgery); gastric outlet obstruction (chronic scarring at the pylorus causing recurrent vomiting, dehydration, and electrolyte disturbance — rare with modern medical therapy); and penetrating ulcer (posterior duodenal ulcer penetrating into the pancreas causing constant back pain and elevated serum amylase).

Stress ulcers (Cushing ulcer in CNS disease, Curling ulcer after major burns) occur in critically ill patients in ICU settings and require prophylactic PPI therapy.

All patients with confirmed peptic ulcer disease (diagnosed by endoscopy with biopsy, or upper GI barium study) require treatment. H. pylori testing is mandatory in all PUD patients — serology, urea breath test, stool antigen, or biopsy rapid urease test (biopsy-based testing requires PPI cessation for 2 weeks and antibiotic cessation for 4 weeks to avoid false-negatives). H. pylori-positive patients receive eradication therapy as the primary intervention.

NSAID-associated ulcers: discontinue the offending NSAID if possible; treat with PPI for 4–8 weeks. If NSAID continuation is medically necessary, switch to a COX-2 selective inhibitor (celecoxib) and co-prescribe a PPI. Patients with prior peptic ulceration or GI bleeding who require long-term NSAIDs should always receive prophylactic PPI co-therapy.

Endoscopic evaluation is essential for: any patient with alarm symptoms (dysphagia, unintended weight loss, persistent vomiting, iron-deficiency anemia, hematemesis/melena, palpable mass); gastric ulcers (to obtain biopsies excluding malignancy); patients over 55 with new-onset dyspepsia; and inadequate response to 4–8 weeks of empiric PPI therapy. Urgent endoscopy (within 12–24 hours) is required for hemodynamically significant upper GI bleeding. Elective endoscopy is appropriate for uncomplicated dyspepsia evaluation in younger patients after non-invasive H. pylori testing.

Proton pump inhibitor (PPI) therapy is the cornerstone of ulcer healing. Standard doses — omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, esomeprazole 40 mg, or rabeprazole 20 mg — taken 30–60 minutes before breakfast reduce gastric acid to levels permitting ulcer healing. Duration: 4 weeks for duodenal ulcers, 8 weeks for gastric ulcers. High-dose PPI (double dose bid) is used for severe ulcer disease or bleeding ulcers during acute management.

H. pylori eradication regimens: Standard first-line in regions with clarithromycin resistance <15%: PPI + clarithromycin 500 mg + amoxicillin 1g (or metronidazole 500 mg) twice daily for 14 days — eradication rate 80–90%. Bismuth quadruple therapy (PPI + bismuth subcitrate + metronidazole + tetracycline for 10–14 days) achieves 85–95% eradication and is preferred in areas of high clarithromycin resistance or as second-line rescue therapy. Sequential therapy (PPI + amoxicillin for 5 days, then PPI + clarithromycin + metronidazole for 5 days) achieves comparable eradication. Vonoprazan-based regimens (potassium-competitive acid blockers) have demonstrated superior eradication rates of 90–95% in Japan and are under evaluation globally.

Endoscopic therapy for bleeding ulcers: epinephrine injection plus mechanical (hemoclip) or thermal (heater probe) therapy achieves primary hemostasis in 90–95% of cases. Second-look endoscopy at 24 hours is no longer routine but is performed when clinical re-bleeding is suspected. Over-the-scope clips (OTSC) are used for refractory bleeding. For perforated ulcers: laparoscopic omental patch repair (Graham patch) is the preferred emergency approach in stable patients; open repair required for large perforations or haemodynamic instability.

Maintenance PPI therapy (half standard dose) is recommended for patients with complicated ulcer history (prior bleeding, multiple ulcers) who require ongoing NSAID use, or those with incomplete H. pylori eradication. H2 receptor antagonists (ranitidine, famotidine) have largely been replaced by PPIs but may be used for nocturnal acid breakthrough or in patients intolerant to PPIs.

Modern medical therapy for peptic ulcer disease achieves excellent outcomes. PPI therapy heals 80–95% of duodenal ulcers at 4 weeks and 85–90% of gastric ulcers at 8 weeks. After successful H. pylori eradication, ulcer recurrence drops from 60–80% per year (without eradication) to under 5% per year, essentially curing the underlying cause in H. pylori–positive patients. This dramatic improvement in recurrence rate represents one of the most significant advances in gastroenterology of the past four decades.

Endoscopic hemostasis for bleeding peptic ulcers reduces 30-day mortality from approximately 10% (pre-endoscopy era) to 2–5% in modern series, and the need for emergency surgical intervention from 30% to under 5%. The NNT (number needed to treat) with H. pylori eradication to prevent one recurrent ulcer bleed is approximately 7, making it one of the most cost-effective preventive interventions in gastroenterology.

For NSAID-related ulcers, cessation of the offending agent combined with 8 weeks of PPI therapy heals over 90% of ulcers. When NSAIDs cannot be stopped, co-prescription of a PPI reduces the risk of NSAID-related ulcer complications by over 60% compared to NSAID alone, as demonstrated in multiple randomised trials.

Untreated peptic ulcer disease carries significant complication risks: hemorrhage occurs in 15–20% of ulcer patients over their lifetime, with 5–10% in-hospital mortality; perforation in 1–5%; gastric outlet obstruction in under 1%. Prompt diagnosis and treatment substantially mitigate these risks.

PPI side effects: generally well tolerated for short courses. Long-term PPI use (>12 months) is associated with: Clostridium difficile infection (RR 1.4–2.0), community-acquired pneumonia (modest increase), hypomagnesemia (rare, <1%), vitamin B12 deficiency (reduced intrinsic factor–mediated absorption over years), reduced calcium absorption theoretically linked to fracture risk at very high doses, and chronic kidney disease (observational association, causality unclear). The clinical importance of these associations must be balanced against the clear benefits of acid suppression for genuine indications.

H. pylori eradication antibiotic side effects: diarrhoea (10–20%), nausea, metallic taste, and Candida overgrowth are common with clarithromycin-containing regimens. Penicillin allergy requires amoxicillin substitution (metronidazole or tetracycline). Clostridium difficile diarrhoea is rare with short 10–14 day eradication courses but possible in older or hospitalised patients. Bismuth compounds cause black stools and tongue discolouration (expected and harmless).

Surgical risks: laparoscopic Graham patch repair carries 30-day mortality of 5–15% for perforated ulcer depending on patient age, comorbidity, and perforation-to-surgery interval; morbidity (wound infection, leak, ileus) occurs in 10–20%. Emergency surgery for haemorrhage uncontrolled by endoscopy carries higher risk, particularly in elderly or anticoagulated patients.

All patients with peptic ulcer disease require confirmation of H. pylori eradication 4–6 weeks after completing eradication therapy. Non-invasive testing (urea breath test or stool antigen) is preferred; serology is not useful for confirming eradication. Repeat endoscopy is mandatory for gastric ulcers at 8–12 weeks after treatment to confirm healing and exclude underlying malignancy — incomplete healing or irregular ulcer margins require multiple biopsies.

For duodenal ulcers, routine repeat endoscopy after treatment is not required if symptoms have resolved and H. pylori eradication is confirmed. Patients with complicated ulcer disease (prior bleeding, perforation) or those requiring long-term NSAID therapy should receive maintenance PPI therapy and annual clinical review. Symptom recurrence after apparently successful treatment should prompt repeat H. pylori testing (antibiotic resistance, reinfection) and consideration of alternative diagnoses including gastric cancer, Zollinger-Ellison syndrome (gastrinoma), or functional dyspepsia.

Lifestyle modifications recommended include: cessation of smoking (which impairs ulcer healing and doubles recurrence risk), alcohol moderation, avoidance of NSAIDs unless co-prescribed with PPI, and avoidance of dietary triggers (caffeinated and carbonated beverages, spicy foods) during symptomatic periods. Stress reduction is advisable, as psychosocial stress activates the HPA axis with consequent effects on acid secretion and mucosal defence.

Peptic ulcer disease treatment costs range from very affordable for outpatient medical therapy to significant for hospitalised bleeding or perforated ulcer management. In India, a 14-day H. pylori eradication course costs USD 10–40 for medications; a urea breath test for confirmation of eradication costs USD 20–60; standard PPI therapy (omeprazole or pantoprazole) costs under USD 5–15 per month. Upper GI endoscopy for diagnosis costs USD 150–450 at accredited gastroenterology centres. Emergency hospitalisation for bleeding ulcer (EGD with haemostasis, 2–5 day admission) costs USD 500–2,500.

In the United States, an EGD for ulcer diagnosis costs USD 1,500–3,500 out-of-pocket; emergency hospitalisation for bleeding ulcer including ICU care, transfusions, and endoscopy costs USD 15,000–60,000. PPI medications (branded) cost USD 150–300 per month; generic omeprazole and pantoprazole cost USD 10–30 per month. In the UK, NHS prescriptions for PPIs cost GBP 9.90 per item (standard prescription charge); endoscopy is NHS-funded on clinical need. Private EGD: GBP 400–900.

For patients travelling internationally to investigate persistent dyspepsia or confirm ulcer diagnosis, all-inclusive packages at JCI-accredited Indian or Thai hospitals — including consultation, blood tests, EGD with biopsies, H. pylori testing, and 14-day eradication therapy — cost USD 400–900, delivering substantial savings compared to US or Australian private pricing.

H2 receptor antagonists (famotidine, ranitidine — prior to its global withdrawal due to NDMA contamination, cimetidine) provide acid suppression less potent than PPIs and are appropriate for mild dyspepsia or nocturnal acid breakthrough. Their healing rates for active ulcers are inferior to PPIs (70–80% at 8 weeks vs. 90–95% for PPIs).

Sucralfate — an aluminium salt that polymerises in the acidic gastric environment to form a protective barrier over the ulcer base — is an alternative cytoprotective agent, particularly for stress ulcer prophylaxis in critically ill patients (comparable to PPIs in some meta-analyses). Misoprostol (a synthetic prostaglandin E1 analogue) protects the gastric mucosa against NSAID-induced damage but causes significant diarrhoea and is rarely used for this purpose due to intolerance.

For patients with refractory ulcers failing two eradication attempts, culture-guided therapy based on antibiotic sensitivity testing of H. pylori biopsies directs salvage regimens. Levofloxacin-based triple therapy or rifabutin-containing regimens are used in this setting. Zollinger-Ellison syndrome (gastrinoma secreting excess gastrin driving massive acid hypersecretion) must be excluded in patients with refractory or multiple ulcers, particularly in the distal duodenum and jejunum — serum fasting gastrin and secretin stimulation test are the primary screening investigations.